Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14978932rdf:typepubmed:Citationlld:pubmed
pubmed-article:14978932lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:14978932lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:14978932lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:14978932lifeskim:mentionsumls-concept:C1955905lld:lifeskim
pubmed-article:14978932lifeskim:mentionsumls-concept:C2248809lld:lifeskim
pubmed-article:14978932lifeskim:mentionsumls-concept:C1880019lld:lifeskim
pubmed-article:14978932pubmed:issue12lld:pubmed
pubmed-article:14978932pubmed:dateCreated2004-2-24lld:pubmed
pubmed-article:14978932pubmed:abstractTextIn Ph(+) CML patients who achieved complete cytogenetic response (CCR) with interferon-alpha (IFN) treatment, how long the treatment should be continued has not well been investigated. We report here 2 CML cases who stopped the treatment after CCR had been sustained with IFN for 2-3 years. A 49-year-old male (case 1) achieved CCR 6 months after the initiation of IFN treatment. CCR had been maintained for 3 years, and then the treatment was ceased. CCR has been sustained without any therapy for 4 years. In this case, RT-PCR became negative half a year after achievement of CCR, and since then negative RT-PCR has been maintained. In case 2, a 50-year-old male, CCR was achieved after 8 years of IFN treatment, and maintained for 2 years. One month after cessation of the treatment, CML relapsed cytogenetically. In case 2, negative RT-PCR results were not maintained during the period of CCR. In case 1, the levels of T-cells for PR 1 were undetectable in the peripheral blood.lld:pubmed
pubmed-article:14978932pubmed:languagejpnlld:pubmed
pubmed-article:14978932pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14978932pubmed:citationSubsetIMlld:pubmed
pubmed-article:14978932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14978932pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14978932pubmed:statusMEDLINElld:pubmed
pubmed-article:14978932pubmed:monthDeclld:pubmed
pubmed-article:14978932pubmed:issn0485-1439lld:pubmed
pubmed-article:14978932pubmed:authorpubmed-author:IijimaKimikoKlld:pubmed
pubmed-article:14978932pubmed:authorpubmed-author:HiraiHisamaru...lld:pubmed
pubmed-article:14978932pubmed:authorpubmed-author:UsukiKensukeKlld:pubmed
pubmed-article:14978932pubmed:authorpubmed-author:UrabeAkioAlld:pubmed
pubmed-article:14978932pubmed:authorpubmed-author:KandaYoshinob...lld:pubmed
pubmed-article:14978932pubmed:authorpubmed-author:IkiSeikoSlld:pubmed
pubmed-article:14978932pubmed:issnTypePrintlld:pubmed
pubmed-article:14978932pubmed:volume44lld:pubmed
pubmed-article:14978932pubmed:ownerNLMlld:pubmed
pubmed-article:14978932pubmed:authorsCompleteYlld:pubmed
pubmed-article:14978932pubmed:pagination1161-5lld:pubmed
pubmed-article:14978932pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:meshHeadingpubmed-meshheading:14978932...lld:pubmed
pubmed-article:14978932pubmed:year2003lld:pubmed
pubmed-article:14978932pubmed:articleTitle[Chronic myelogenous leukemia in cessation of therapy after sustained CCR with interferon].lld:pubmed
pubmed-article:14978932pubmed:affiliationDivision of Hematology, NTT Kanto Medical Center.lld:pubmed
pubmed-article:14978932pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14978932pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:14978932pubmed:publicationTypeCase Reportslld:pubmed